AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 141 min read$IDYA

IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma (IDYA:NASDAQ)

Stifel resumed coverage of IDEAYA Biosciences (IDYA) with a Buy rating, citing potential of its combo treatment for uveal melanoma. The firm set a $48 price target, implying ~40% upside from Oct. 13 close.

Original reporting
seekingalpha.com
Published Oct 14, 2026, 4:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IDYA
Bullish
high confidence
Mentioned
$IDYA
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IDYABullishMed
01

Why it matters

Stifel's new Buy rating and $48 target suggest a material revaluation of the stock.

02

Market read

Analyst upgrade provides a fresh catalyst for traders to consider buying IDEAYA.

03

What to watch

Regulatory timelines and competition in uveal melanoma therapies could limit upside.

Relevance 6/10Novelty 5/10Timing: today

Background

IDEAYA Biosciences is developing a combo of darovasertib and crizotinib for metastatic uveal melanoma.

Company-level read

Ticker impact

$IDYABullishHigh confidence
Context

Stifel resumed coverage of IDEAYA Biosciences at Buy with a new $48 price target, indicating an upgrade and potential upside.

Expected impact

likely upward pressure as investors price in the $48 target

Evidence & confidence

Buy rating and 40% upside target are fresh, actionable signals for traders.

Market effects

Sector

Positive sentiment for biotech and oncology-focused companies.

Regional

Minimal, limited to US biotech investors.

Global

Low, confined to niche therapeutic area.

Counterpoint

What could challenge this read

The upgrade may be premature if clinical data does not meet expectations.

Key entities

  • company
    IDEAYA Biosciences

    Biotech firm developing uveal melanoma therapy.

  • analyst
    Stifel

    Equity research firm that upgraded IDEAYA.

Read at source← All news

Related articles

OCT 19
$IDYAMedAI 8/10

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA Biosciences and Servier presented clinical trial data at ESMO 2026, showing positive results for darovasertib in treating uveal melanoma. OptimUM-01 data showed 7.4-month PFS and 27.1-month mOS in treatment-naïve patients. OptimUM-02 data confirmed improvements in ORR and PFS across subgroups. OptimUM-09 data demonstrated 57% eye preservation rate and 66% radiation dose reduction in primary UM patients.

prnewswire.com2 min
SEP 25
$IDYAMedAI 8/10

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

IDEAYA Biosciences (IDYA) reported a widened quarterly net loss but maintains strong liquidity with $1.24B in cash. It dosed the first patient in a Phase 3 trial for darovasertib in uveal melanoma, sharing costs with partner Servier. The company is advancing its oncology pipeline while managing R&D costs, with regulatory approvals and commercial execution being key to its success.

insidermonkey.com3 min